Peptides for Weight Loss: How GLP-1 and GIP Peptides Work (2026)
The term “peptides for weight loss” now covers two very different groups of compounds, and mixing them up is the most common mistake people make. One group includes drugs that have passed large human trials and won FDA approval. The other includes older or investigational molecules whose weight-loss data range from thin to disappointing.
Sorting them by evidence, not by hype, changes the whole picture.
The Compound Universe Take: The peptides with real weight-loss evidence are the incretin-based receptor agonists, led by semaglutide and tirzepatide, both FDA-approved for chronic weight management after large randomized trials. Retatrutide is a promising investigational triple agonist still in trials. Growth-hormone-axis peptides like tesamorelin target visceral fat in a narrow approved population, while AOD-9604 failed its main weight-loss trial. Most non-approved options are sold for research use only.
New to the topic? This overview maps the category. When you want the compounds ranked head to head, see the best peptides for weight loss ranked by evidence.
What peptides for weight loss actually are
A peptide is a short chain of amino acids that acts as a signaling molecule. The peptides studied for body weight fall into two mechanistic families.
The first family mimics gut and pancreatic hormones. GLP-1 receptor agonists slow gastric emptying and reduce appetite, so people eat less without forcing it. Newer molecules add a second or third receptor target to the same idea.
The second family works through the growth-hormone axis. These peptides prompt the body to release its own growth hormone, which shifts fat metabolism, most visibly around the abdomen.
| Peptide | What it is studied for | Evidence tier |
|---|---|---|
| Semaglutide | Chronic weight management | Human RCT + FDA-approved |
| Tirzepatide | Chronic weight management | Human RCT + FDA-approved |
| Retatrutide | Obesity (triple agonist) | Human phase 2 (investigational) |
| Tesamorelin | Visceral fat in HIV lipodystrophy | Human RCT + FDA-approved (narrow) |
| AOD-9604 | Fat loss (GH fragment) | Human trial (missed endpoint) |
The peptides most studied for weight loss
Semaglutide: the GLP-1 agonist with a regulatory record
Semaglutide is a GLP-1 receptor agonist and the compound that reset expectations for weight-loss pharmacology. In the STEP 1 trial, adults with overweight or obesity lost a mean of roughly 15 percent of body weight over 68 weeks on weekly semaglutide, versus about 2.4 percent on placebo [1]. Evidence tier: Human RCT + Regulatory. It is FDA-approved for chronic weight management (marketed as Wegovy).
The mechanism is appetite, not stimulation. GLP-1 signaling reduces hunger and slows stomach emptying, which lowers calorie intake.
Tirzepatide: the dual GIP and GLP-1 agonist
Tirzepatide adds a second target. Tirzepatide activates both the GIP and GLP-1 receptors, and in the SURMOUNT-1 trial the 15 mg dose produced a mean weight reduction near 21 percent at 72 weeks, compared with about 3 percent on placebo [2]. Evidence tier: Human RCT + Regulatory. It is FDA-approved for chronic weight management (marketed as Zepbound).
On the numbers reported so far, tirzepatide sits at the top of the approved options for magnitude of weight change.
Retatrutide: the investigational triple agonist
Retatrutide targets three receptors at once: GIP, GLP-1, and glucagon. In a 48-week phase 2 trial, the 12 mg dose produced a mean weight reduction around 24 percent [3]. Evidence tier: Human phase 2 (investigational).
Read the stage carefully. Retatrutide is not approved, its phase 3 program is ongoing, and phase 2 results can shift under larger, longer testing. It is the most-watched molecule in the pipeline, not a settled option.
Tesamorelin: the growth-hormone-releasing peptide
Tesamorelin is a growth-hormone-releasing factor analog. Tesamorelin stimulates endogenous growth hormone release, which reduces visceral adipose tissue. In a randomized trial in people with HIV-associated abdominal fat accumulation, it lowered visceral fat versus placebo [4]. Evidence tier: Human RCT + Regulatory (narrow indication).
Its FDA approval is specific to reducing excess visceral abdominal fat in HIV lipodystrophy. It is not approved as a general weight-loss drug, and its trials did not test that use.
AOD-9604: the fragment that missed its endpoint
AOD-9604 is a synthetic fragment of the growth hormone molecule, marketed for years on animal fat-loss data. Human testing told a different story: it was well tolerated in safety studies, but its largest phase 2b obesity trial failed to beat placebo on the primary weight-loss endpoint, and formal development was halted [5]. Evidence tier: Human trial (missed primary endpoint). It is not FDA-approved and is sold for research use only.
Approved versus investigational: how the evidence divides
The honest split is regulatory. Semaglutide and tirzepatide have crossed the bar of large randomized trials plus FDA review for weight management. Retatrutide is promising but unproven at phase 3. Tesamorelin is approved only for a narrow HIV indication. AOD-9604 did not clear its efficacy trial.
Read this before the hype: Several compounds discussed here are not FDA-approved for weight loss and are sold “for research use only.” This article summarizes published research; it is not medical advice, a dosing guide, or an endorsement of use. Legal status varies by compound and jurisdiction and is changing.
| Peptide | Primary mechanism | Evidence maturity | Regulatory status (US) |
|---|---|---|---|
| Semaglutide | GLP-1 receptor agonist | Phase 3 RCT | FDA-approved (weight management) |
| Tirzepatide | GIP + GLP-1 agonist | Phase 3 RCT | FDA-approved (weight management) |
| Retatrutide | GIP + GLP-1 + glucagon agonist | Phase 2 | Investigational |
| Tesamorelin | GH-releasing factor analog | Phase 3 RCT (HIV) | FDA-approved (HIV visceral fat only) |
| AOD-9604 | GH fragment (lipolysis) | Failed phase 2b | Not approved; research use only |
Key takeaways
- Tirzepatide reported the largest approved weight loss, near 21 percent at the top dose, by acting as a dual GIP and GLP-1 receptor agonist [2].
- Semaglutide is a GLP-1 receptor agonist with a mean reduction around 15 percent in its phase 3 trial and FDA approval for chronic weight management [1].
- Retatrutide is an investigational triple agonist; its phase 2 figure near 24 percent is early data, not a validated result [3].
- Tesamorelin targets visceral adipose tissue and is approved only for HIV-associated lipodystrophy, not general obesity [4].
- Growth-hormone fragments like AOD-9604 carry strong animal claims but weak human proof, having missed the primary endpoint in a phase 2b trial [5].
Frequently asked questions
What are peptides for weight loss?
They are short amino-acid signaling molecules studied for reducing body weight. The best-evidenced ones are incretin receptor agonists such as semaglutide and tirzepatide; others target the growth-hormone axis.
Which weight-loss peptide has the strongest evidence?
Semaglutide and tirzepatide have the strongest evidence, because both passed large phase 3 trials and hold FDA approval for chronic weight management. Tirzepatide reported the higher average weight loss of the two.
Is retatrutide available or approved?
No. Retatrutide is investigational and still in clinical trials. Its phase 2 weight-loss numbers are encouraging but not yet confirmed by phase 3 testing or regulators.
Does tesamorelin cause weight loss?
Tesamorelin reduces visceral abdominal fat in people with HIV-associated lipodystrophy, its approved use. It has not been established as a general weight-loss treatment in the wider population.
Does AOD-9604 work for fat loss?
Human evidence is weak. AOD-9604 was well tolerated in safety studies but failed to beat placebo on its main weight-loss endpoint, and development was discontinued.
Are these peptides legal?
Semaglutide and tirzepatide are FDA-approved prescription drugs. Others, including AOD-9604 and unapproved sources of these compounds, are commonly sold for research use only, and legal status varies by jurisdiction and is changing.
Interest in peptides for weight loss sits where incretin biology meets obesity medicine, with GLP-1 receptor agonists such as semaglutide, dual GIP and GLP-1 agonists such as tirzepatide, and the investigational glucagon-including triple agonist retatrutide anchoring the strongest human data, while growth-hormone-axis peptides like tesamorelin, approved narrowly for HIV-related visceral adipose tissue, and the growth hormone fragment AOD-9604 sit at the weaker or unproven end; Compound Universe tracks each compound against appetite regulation, gastric emptying, lipolysis, and regulatory status so the category reflects trial evidence rather than marketing.
The bottom line on peptides for weight loss is that the category is real but uneven: two approved incretin drugs carry strong human trial evidence, one triple agonist is promising but unproven, and the growth-hormone-axis options are either narrowly approved or unsupported. Match any compound to its evidence tier before you trust a claim about it. For the ranked head-to-head, Compound Universe’s tirzepatide research summary and the question of which compounds are legal to buy fill in the next layer.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID 33567185.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID 35658024.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315.
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV (tesamorelin). N Engl J Med. 2007. PMID 18057338.
- Stier H, et al. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013. (Safety and tolerability data across the AOD9604 human program. Note: the separate sponsor-run phase 2b obesity trial in 2007 did not meet its primary weight-loss endpoint versus placebo, and the obesity program was subsequently discontinued.)